Potential applications of the gut microbiota in the diagnosis and treatment of colorectal cancer: recent advances and prospects
Colorectal cancer is the malignant tumor of the digestive system with the highest incidence. With the faster
pace of life and changes in diet, the incidence and mortality of colorectal cancer are also increasing year by year, seriously
threatening human health. There are a large number of intestinal microbes in the human intestine. These microbes interact with
host cells to regulate many physiological processes, such as energy harvest, metabolism and immune response. Abnormal changes
in the internal or external environment of the host, such as unclean diet, unhealthy lifestyle, or the abuse of antibiotics, will
destroy the homeostasis of the intestinal microbiota, trigger the imbalance of the intestinal flora, and then lead to the occurrence
of many diseases including colorectal cancer. In recent years, the role of intestinal microbiota in the occurrence and development
of colorectal cancer has attracted much attention. With the development of genomics technologies, research on the intestinal
microbiota of colorectal cancer has achieved rapid development. More and more studies have shown that there will be an
abnormal increase in the number of certain intestinal microbiota in patients with colorectal cancer; and improving the imbalance
of intestinal flora can reduce the incidence of colorectal cancer and inhibit the progression of tumors. Therefore, intestinal
microbes are expected to become biomarkers for colorectal cancer screening and prognosis prediction, and therapeutic targets.
This article summarizes the latest progress in the application of gut microbiota in colorectal cancer in the past five years. This
article provides an overview of recent research focusing on the application of gut microbiota in the diagnosis and treatment of
colorectal cancer in the past five years and highlights the advances achieved.
Abstract：Colorectal cancer is the malignant tumor of the digestive system with the highest incidence. With the faster
pace of life and changes in diet, the incidence and mortality of colorectal cancer are also increasing year by year, seriously
threatening human health. There are a large number of intestinal microbes in the human intestine. These microbes interact with
host cells to regulate many physiological processes, such as energy harvest, metabolism and immune response. Abnormal changes
in the internal or external environment of the host, such as unclean diet, unhealthy lifestyle, or the abuse of antibiotics, will
destroy the homeostasis of the intestinal microbiota, trigger the imbalance of the intestinal flora, and then lead to the occurrence
of many diseases including colorectal cancer. In recent years, the role of intestinal microbiota in the occurrence and development
of colorectal cancer has attracted much attention. With the development of genomics technologies, research on the intestinal
microbiota of colorectal cancer has achieved rapid development. More and more studies have shown that there will be an
abnormal increase in the number of certain intestinal microbiota in patients with colorectal cancer; and improving the imbalance
of intestinal flora can reduce the incidence of colorectal cancer and inhibit the progression of tumors. Therefore, intestinal
microbes are expected to become biomarkers for colorectal cancer screening and prognosis prediction, and therapeutic targets.
This article summarizes the latest progress in the application of gut microbiota in colorectal cancer in the past five years. This
article provides an overview of recent research focusing on the application of gut microbiota in the diagnosis and treatment of
colorectal cancer in the past five years and highlights the advances achieved.
王科伟，董明. 肠道微生物群在结直肠癌诊治中的潜在应用：最新进
展和前景[J]. 肿瘤代谢与营养电子杂志, 2021, 8(1): 11-16.
Wang Kewei, Dong Ming. Potential applications of the gut microbiota in the diagnosis and treatment of colorectal cancer: recent advances and prospects. Electron J Metab Nutr Cancer, 2021, 8(1): 11-16.
